definiens: shall mean the Patent Rights listed onSchedule 1(b ), the Patents licensed to [COMPANY] under the Listed [COMPANY] ThirdParty Agreements, and all other Patents now or in the future Controlled byAlnylam that Cover RNAi technology, products or processes, including, Patentsthat Cover ( a ) the general structure, architecture, or design of nucleic acidbased molecules which engage RNAi mechanisms in a cell ; ( b ) chemicalmodifications of nucleic acids ( including any modification to the base, sugar orinternucleoside linkage, nucleotide mimetics, and any end modifications ) whichdo not abolish the RNAi activity of the nucleic acid molecules in ( a ) ; ( c)manufacturing techniques for the nucleic acid based molecules or chemicalmodifications of ( a ) and ( b ) ; and ( d ) all uses or applications of nucleic acidbased molecules or chemical modifications in ( a ) or ( b ) ; but excluding Patentswhich relates solely to ( i ) a specific Target or small group of Targets ; or ( ii)delivery technologies which may be broadly employed for delivery of nucleic acidbased molecules